BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines gross Intangibles — Developed Technology Rights ($M) ($M)
Form 10-Q / 10-K Intangible Assets Note (XBRL)
Latest, Q2 2026
79.5
Period ended Jun 30, 2026
Change on a year earlier
+4.2%
76.3 in Q2 2025
History
22 quarters
Since Q4 2020
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gross Intangibles — Developed Technology Rights ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 79.5 | +4.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 78.4 | +24.1% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 77.5 | +23.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 76.6 | +18.2% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 76.3 | +20.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 63.2 | -0.3% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 62.9 | -2.2% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 64.8 | +11.0% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 63.1 | +27.7% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 63.4 | +53.1% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 64.3 | +56.1% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 58.4 | +44.6% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 49.4 | +17.6% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 41.4 | -4.8% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 41.2 | -5.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2022 | Sep 30, 2022 | 40.4 | +304.0% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 42 | +460.0% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 43.5 | – | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 43.4 | – | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 10 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 7.50 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Gross Intangibles — Developed Technology Rights ($M) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/intang_gross_tech
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.